MYGN Q2 2021 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$454M

Q2 2021 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$189M+103.2% YoY

Gross Profit

$136M71.6% margin

Operating Income

-$21M-11.0% margin

Net Income

-$5M-2.5% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+9.4%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$9M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$458M

Stockholders' Equity

$903M

Cash & Equivalents

$118M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$189M	$93M	+103.2%
Gross Profit	$136M	$57M	+140.2%
Operating Income	-$21M	-$68M	+69.5%
Net Income	-$5M	-$55M	+91.5%

Revenue Segments

Molecular Diagnostic Testing

$179M94%

Molecular Diagnostic Prenatal Testing

$11M6%

Geographic Segments

UNITED STATES

$165M87%

Non-US

$25M13%